John Bradley Sorenson - 02 May 2025 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
EVP, Global Operations
Signature
/s/ Susan Thompson, Attorney-in-Fact
Issuer symbol
BSX
Transactions as of
02 May 2025
Net transactions value
-$679,213
Form type
4
Filing time
06 May 2025, 16:37:45 UTC
Previous filing
19 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sorenson John Bradley EVP, Global Operations 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH /s/ Susan Thompson, Attorney-in-Fact 05 May 2025 0001629277

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $0 +4,204 +20% $0.000000 25,195 02 May 2025 Direct F1
transaction BSX Common Stock Tax liability $201,256 -1,918 -7.6% $104.93 23,277 02 May 2025 Direct
transaction BSX Common Stock Sale $477,957 -4,572 -20% $104.54 18,705 05 May 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Restricted Stock Units Options Exercise $0 -4,204 -50% $0.000000 4,204 02 May 2025 Common Stock 4,204 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.
F2 The transaction reported in this Form 4 was effected pursuant to a pre-established Rule 10b5-1 trading plan adopted on August 9, 2024.
F3 Shares of common stock will be issued to the reporting person in four equal annual installments beginning on May 2, 2023, the first anniversary of the date of grant.